BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 179 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $408,000 | +30.8% | 57,641 | +30.3% | 0.00% | – |
| Q2 2023 | $312,000 | -48.2% | 44,244 | -38.7% | 0.00% | – |
| Q1 2023 | $602,000 | -38.2% | 72,144 | -15.0% | 0.00% | – |
| Q4 2022 | $974,000 | +189.0% | 84,834 | +217.6% | 0.00% | – |
| Q3 2022 | $337,000 | -61.0% | 26,709 | -67.2% | 0.00% | – |
| Q2 2022 | $863,000 | +2.9% | 81,552 | +58.1% | 0.00% | – |
| Q1 2022 | $839,000 | -23.3% | 51,579 | -34.7% | 0.00% | – |
| Q4 2021 | $1,094,000 | +32.0% | 78,954 | +37.0% | 0.00% | – |
| Q3 2021 | $829,000 | +47.2% | 57,632 | +61.9% | 0.00% | – |
| Q2 2021 | $563,000 | +29.4% | 35,595 | -16.8% | 0.00% | – |
| Q1 2021 | $435,000 | +88.3% | 42,784 | +37.8% | 0.00% | – |
| Q4 2020 | $231,000 | +89.3% | 31,057 | -12.5% | 0.00% | – |
| Q3 2020 | $122,000 | +69.4% | 35,510 | +134.3% | 0.00% | – |
| Q2 2020 | $72,000 | -29.4% | 15,159 | -70.3% | 0.00% | – |
| Q1 2020 | $102,000 | +410.0% | 50,985 | +790.7% | 0.00% | – |
| Q4 2019 | $20,000 | +81.8% | 5,724 | +48.6% | 0.00% | – |
| Q3 2019 | $11,000 | +37.5% | 3,852 | +78.9% | 0.00% | – |
| Q2 2019 | $8,000 | -85.7% | 2,153 | -69.0% | 0.00% | – |
| Q1 2019 | $56,000 | +55.6% | 6,937 | +54.3% | 0.00% | – |
| Q4 2018 | $36,000 | -35.7% | 4,495 | -39.6% | 0.00% | – |
| Q3 2018 | $56,000 | +1766.7% | 7,445 | +1702.7% | 0.00% | – |
| Q2 2018 | $3,000 | -70.0% | 413 | -79.4% | 0.00% | – |
| Q1 2018 | $10,000 | +100.0% | 2,000 | +80.8% | 0.00% | – |
| Q4 2017 | $5,000 | -87.8% | 1,106 | -85.7% | 0.00% | – |
| Q3 2017 | $41,000 | +1266.7% | 7,720 | +1574.6% | 0.00% | – |
| Q2 2017 | $3,000 | -90.0% | 461 | -86.9% | 0.00% | – |
| Q1 2017 | $30,000 | +15.4% | 3,532 | -14.4% | 0.00% | – |
| Q4 2016 | $26,000 | – | 4,128 | +9500.0% | 0.00% | – |
| Q3 2016 | $0 | -100.0% | 43 | -85.7% | 0.00% | – |
| Q1 2016 | $1,000 | -93.3% | 300 | -80.1% | 0.00% | – |
| Q4 2015 | $15,000 | -60.5% | 1,511 | -54.6% | 0.00% | – |
| Q3 2015 | $38,000 | +660.0% | 3,330 | +732.5% | 0.00% | – |
| Q2 2015 | $5,000 | +66.7% | 400 | +33.3% | 0.00% | – |
| Q1 2015 | $3,000 | -93.3% | 300 | -91.4% | 0.00% | – |
| Q2 2014 | $45,000 | +21.6% | 3,500 | 0.0% | 0.00% | – |
| Q1 2014 | $37,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |